FIXX - Homology announces peer-reviewed preclinical data publication on its AAVHSC16 capsid

• Homology Medicines ( NASDAQ: FIXX ) on Tuesday announced peer-reviewed publication of data on its AAVHSC16 capsid.
• FIXX stock earlier gained as much as 9.8% to a session high of $2.01 and was last up 3.3% in afternoon trading.
• According to the data, AAHVSC16 showed low levels of tropism to the liver while maintaining robust distribution to the central nervous system (CNS) and peripheral organs following a single intravenous injection in preclinical studies with rodents and primates.
• The preclinical data was peer-reviewed and published in the Molecular Therapy - Methods & Clinical Development journal .
• AAVHS16 is a capsid, which is the protein shell of a virus that encloses its genetic material. AAVHS stands for adeno-associated virus and hematopoietic stem cells, which are naturally occurring stem cells. FIXX's technology uses a family of 15 these types of cells to deliver genetic medicines.
• "In the case of AAVHSC16 with its ability to reach key tissues without targeting the liver in preclinical models, we can potentially expand into additional disease areas where we want to deliver to the CNS, cardiac tissue, or muscle while avoiding exposure in the liver," said FIXX chief scientific officer Albert Seymour.

For further details see: